AZN - ASTRAZENECA PLC

201.76
-1.970   -0.976%

Share volume: 2,220,584
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$203.73
-1.97
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-3.21%
1 Month
7.63%
3 Months
117.48%
6 Months
117.48%
1 Year
117.48%
2 Year
117.48%
Key data
Stock price
$201.76
P/E Ratio 
N/A
DAY RANGE
$197.10 - $201.99
EPS 
N/A
52 WEEK RANGE
$92.46 - $212.71
52 WEEK CHANGE
$117.48
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$1,878,313
AVERAGE 30 VOLUME 
$2,488,048
Company detail
CEO: Pascal Soriot
Region: US
Website: astrazeneca.com
Employees: 83,500
IPO year: 2026
Issue type:
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AstraZeneca PLC focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. The company serves primary care and specialty care physicians through distributors in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.

Recent news